Hydroxyurea Therapy Offers Effective Disease Management of Sickle Cell Anemia

Conclusive data of a key clinical trial studying the drug's efficacy show that hydroxyurea therapy offers safe and effective disease management of sickle cell anemia (SCA).

And it also reduces the risk of stroke, prompting early termination. The National Heart Lung and Blood Institute (NHLBI) officials issued the announcement about one year before the study was originally scheduled to end. Going by the title TWiTCH (TCD With Transfusions Changing to Hydroxyurea), the Phase III randomized clinical trial at 25 medical centers in the U.S. and Canada compared standard therapy (monthly erythrocyte transfusions) with the alternative (daily hydroxyurea) for children with elevated transcranial Doppler (TCD) velocities and high risk of stroke.

Risk of Recurrent Blockage of Brain Blood in Sickle Cell Anemia Children can be Reduced Through Regular Blood Transfusions
A new study suggests that providing regular blood transfusions can prevent recurrent blockage of brain blood among children with sickle cell anemia.

"Early results indicate that TWiTCH is a success. Hydroxyurea works as well as blood transfusions to lower TCD velocities, which lowers the risk of the child having a stroke," said Russell E. Ware, MD, PhD, principal investigator of the study and director of Hematology at Cincinnati Children's Hospital Medical Center, which served as the study's Medical Coordinating Center.

"A group of outside experts has been reviewing the TWiTCH data every few months to ensure the safety of children in the clinical trial and to monitor the data," Ware explained. "This group met recently and after careful consideration of the interim data results, recommended that the study be stopped since hydroxyurea worked as well as transfusions to lower TCD velocities."

The NHLBI and National Institutes of Health (NIH) agreed with the recommendation. "No child should ever suffer a stroke, which is why it was so important for the NHLBI to support the TWiTCH trial," said Gary Gibbons, MD, director of the NHLBI. "This critical research finding opens the door to more treatment options for clinicians trying to prevent strokes in children living with the sickle cell disease."

Sickle Cell Anemia Drug Reduces Hospitalizations
Drug hydroxyurea proven effective for sickle cell anemia treatment in adults and children was found to reduce hospitalizations and cut annual estimated medical costs by 21 percent, says report.

The study enrolled its first patient in September 2011 and included children between ages 4 and 16 years with sickle cell anemia and abnormally elevated TCD velocities, which increases their risk of developing a stroke. The current standard therapy for children with elevated TCD velocities is monthly blood transfusions. A total of 121 children were randomized: half received the standard therapy of transfusions while the other half received the alternate treatment with daily hydroxyurea, which has not yet been approved for children with sickle cell anemia.

The clinical data-collection portion of the study was originally scheduled for 24 months, but collection is now being stopped early, after only half of the children have completed the treatment phase.

New Insight into Stroke Risk and Prevention in Young Patients With Sickle Cell Anemia
Monthly blood transfusions combined with daily medication to remove the resulting excess iron remains the best approach for reducing the risk of recurrent strokes in young patients

"We did not know if hydroxyurea would reduce the risk of stroke as well as transfusions, so TWiTCH was an important research study," said Barry R. Davis, MD, PhD, principal investigator for the Data Coordinating Center at the University of Texas Health Science Center at Houston (UTHealth) School of Public Health.

Source-Eurekalert

Efforts to Prevent Sickle Cell Anemia Stroke Can Have Reduced Racial Disparities
Inequality in stroke-related deaths among black and white children radically lessened once ultrasound screening and chronic blood transfusions were included for children with sickle cell anemia.